Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2014
March 2014, Vol 5, No 2
March 2014, Vol 5, No 2
Bevacizumab Does Not Improve Survival in Patients with Newly Diagnosed Glioblastoma
By
Jayson Slotnik, JD, MPH
In the Literature
March 2014, Vol 5, No 2
In early clinical studies, bevacizumab (Avastin) showed clinical activity in patients with recurrent glioblastoma. A new randomized, double-blind, placebo-controlled trial investigated whether the use of bevacizumab would improve the OS and PFS of patients with newly diagnosed glioblastoma (Gilbert MR, et al.
N Engl J Med
. 2014;370:699-708).
Read Article
Gazyva for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology
By
Lisa A. Raedler, PhD, RPh
Drug Updates
March 2014, Vol 5, No 2
Chronic lymphocytic leukemia (CLL), a monoclonal disorder characterized by progressive accumulation and proliferation of functionally incompetent B-cells, is the most frequently diagnosed leukemia in the United States.
Read Article
Implications of the Affordable Care Act for Adult Survivors of Childhood Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
March 2014, Vol 5, No 2
Among adult survivors of childhood cancer, the lack of health insurance is a major obstacle to obtaining the recommended follow-up care. The goal of the Patient Protection and Affordable Care Act (ACA) enacted in 2010 was to broaden insurance coverage for all Americans. A new commentary by Mueller and several health policy experts addressed the questions regarding how several provisions in the ACA could help adult survivors of childhood cancers overcome insurance-based barriers to receiving the recommended follow-up care for patients with cancer (Mueller EL, et al.
J Clin Oncol
. 2014;32:615-617).
Read Article
Nintedanib plus Docetaxel an Effective Combination in Patients with Advanced Non–Small-Cell Lung Cancer
By
Jayson Slotnik, JD, MPH
In the Literature
March 2014, Vol 5, No 2
Currently, the US Food and Drug Administration–approved second-line treatments for non–small-cell lung cancer (NSCLC) include monotherapy with docetaxel (Taxotere), erlotinib (Tarceva), or pemetrexed (Alimta). A recent phase 3 clinical trial explored the safety and efficacy of nintedanib (Vargatef)—a potent oral angiokinase inhibitor—in combination with docetaxel, as a second-line treatment in patients with NSCLC (Reck M, et al.
Lancet Oncol
. 2014;15:143-155).
Read Article
Bortezomib plus Thalidomide Maintenance Therapy Improves Overall Survival in Transplant-Ineligible Patients with Newly Diagnosed Myeloma
By
Jayson Slotnik, JD, MPH
In the Literature
March 2014, Vol 5, No 2
Patients with multiple myeloma (MM) who are not fit to undergo stem-cell transplantation (SCT), typically receive melphalan (Alkeran) plus prednisone in combination with either thalidomide (Thalomid) or bortezomib (Velcade). Recent studies are exploring the clinical benefit of the 4-drug induction regimen of melphalan, prednisone, bortezomib, and thalidomide, followed by maintenance with bortezomib plus thalidomide (VMPT-VT). In a recent phase 3 clinical trial, a total of 511 patients with newly diagnosed MM who were not candidates for SCT were randomized to receive VMPT-VT (N = 254) or bortezomib, melphalan, and prednisone (VMP; N = 257). The patients’ median age was 71 years, and 27% of the patients were aged >75 years (Palumbo A, et al.
J Clin Oncol
. 2014;32:634-640).
Read Article
Biomarker Development and Validation Crucial to Appropriate Use of Emerging Treatments in Oncology
By
Wayne Kuznar
Personalized Medicine
March 2014, Vol 5, No 2
Boston, MA—Biomarker development and validation are essential for the rational use of emerging cancer treatments, said presenters at the second Global Biomarkers Consortium annual conference.
Read Article
Understanding Molecular Subtypes Is Basis for Genomic Medicine in Prostate Cancer
By
Wayne Kuznar
Personalized Medicine
March 2014, Vol 5, No 2
Boston, MA—Incorporating genomics into the practice of medicine requires the demonstration of the ability of biomarkers to impact clinical decision-making, and ensuring that patients receive the best therapy based on genomic findings. Scott A. Tomlins, MD, PhD, Assistant Professor of Pathology and Urology, University of Michigan Medical School, Ann Arbor, reviewed efforts to realize genomic medicine into prostate cancer diagnosis and management at the second Global Biomarkers Consortium annual conference.
Read Article
Encouraging Long-Term Safety Data for Radium-223
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
Results of a study reported at the 2014 Genitourinary Cancers Symposium showed that at 1.5 years after the last injection of this therapy, minimal myelosuppression and minimal nonhematologic adverse events were reported, and there were no reports of cancers of concern, including acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and primary bone cancer
Read Article
QOL Improved with 18 versus 36 Months of Hormonal Therapy in Patients with High-Risk Prostate Cancer, Confirming Earlier Efficacy Evidence
By
Alice Goodman
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
San Francisco, CA—Longer-term follow-up of a large randomized phase 3 trial suggests that quality of life (QOL) is improved when patients with high-risk prostate cancer have a shorter versus longer course of androgen- deprivation therapy (ADT) plus radiotherapy as primary treatment. In this follow-up study, 18 months of ADT were found to improve QOL versus 36 months of ADT when added to radiotherapy.
Read Article
Previous Docetaxel Therapy Thwarts Enzalutamide Activity in CRPC
By
Charles Bankhead
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2014, Vol 5, No 2
San Francisco, CA—Men with castration-resistant prostate cancer (CRPC) had inferior time duration to prostate-specific antigen (PSA) progression and of progression-free survival (PFS) if they received the androgen receptor agonist enzalutamide (Xtandi) after the taxane docetaxel (Taxotere) rather than before, according to data from a retrospective study presented at the 2014 Genitourinary Cancers Symposium.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma